K. Flaherty
Oncology · New England Journal of Medicine · 2006–2020
A researcher in the Science corpus: 39 papers; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 383 citations into it
- Immunology — 194 citations into it
Whom K. Flaherty trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts K. Flaherty overall
Papers from K. Flaherty's perspective
Ordered by how strongly the researchers K. Flaherty trusts endorse each paper. Same corpus, a different order for every researcher.
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (New England Journal of Medicine)
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (New England Journal of Medicine)
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells (Science Translational Medicine)
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
- Signatures of mutational processes in human cancer (Nature)
- Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma (New England Journal of Medicine)
Their papers
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq (2016) — 4,371 citations
- Final version of 2009 AJCC melanoma staging and classification. (2009) — 4,641 citations
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (2011) — 7,483 citations
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma (2010) — 1,767 citations
- Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine (2017) — 1,535 citations
- EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib (2012) — 944 citations
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma (2010) — 3,615 citations
- Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion (2012) — 1,464 citations
- Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. (2012) — 2,135 citations
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) (2011) — 1,402 citations
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations (2012) — 2,686 citations
- Improved survival with MEK inhibition in BRAF-mutated melanoma. (2012) — 1,998 citations
- BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma (2013) — 890 citations
- Improved overall survival in melanoma with combined dabrafenib and trametinib. (2015) — 2,453 citations
- Genomic Classification of Cutaneous Melanoma (2015) — 2,764 citations
- Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. (2010) — 727 citations
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis (2006) — 652 citations
- COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation (2010) — 731 citations
- Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group (2012) — 1,221 citations
- Targeted agents and immunotherapies: optimizing outcomes in melanoma (2017) — 1,125 citations